Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
Authors:
Open Access
- 2 December 2023
- journal article
- review article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 24 (1) , 1-16
Abstract
Objective: The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN). Methods: Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change. Results: The literature search ultimately included 11 drugs, 33 studies and 6 types of drugs, 8 trials with TCAs (imipramine, desipramine), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizers (lithium), and 1 with amphetamine-type appetite suppressant (fenfluramine). The reduction in binge eating episodes was more likely due to these drugs than the placebo, and the SMD was -0.4 (95% CI -0.61 ~ -0.19); the changes in the frequency of vomiting episodes (SMD = -0.16, 95% CI -0.3 ~ -0.03); weight (WMD = -3.05, 95% CI -5.97 ~ -0.13); and depressive symptoms (SMD = -0.32, 95% CI -0.51 ~ -0.13). However, no significant difference was found in dropout due to adverse events (RR = 1.66, 95% CI 1.14 ~ 2.41). Conclusions: This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.Keywords
All Related Versions
This publication has 82 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Efficacy of sertraline for bulimia nervosaInternational Journal of Eating Disorders, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- An Open Trial of Fluoxetine for Adolescents with Bulimia NervosaJournal of Child and Adolescent Psychopharmacology, 2003
- Cognitive‐behavioural, fluoxetine and combined treatment for bulimia nervosa: short‐ and long‐term resultsEuropean Eating Disorders Review, 2002
- Fluoxetine for Bulimia Nervosa Following Poor Response to PsychotherapyAmerican Journal of Psychiatry, 2000
- Effects of Fluvoxamine on Depression, Anxiety, and Other Areas of General Psychopathology in Bulimia NervosaPharmacopsychiatry, 1997
- P-2-39 Fluoxetine treatment of bulimia nervosaEuropean Neuropsychopharmacology, 1995
- Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosaNordic Journal of Psychiatry, 1995
- The file drawer problem and tolerance for null results.Psychological Bulletin, 1979